Selected article for: "antiviral drug candidate and SARS cov"

Author: Sakurai, Yasuteru; Ngwe Tun, Mya Myat; Kurosaki, Yohei; Sakura, Takaya; Inaoka, Daniel Ken; Fujine, Kiyotaka; Kita, Kiyoshi; Morita, Kouichi; Yasuda, Jiro
Title: 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
  • Cord-id: yw19jqm8
  • Document date: 2020_10_28
  • ID: yw19jqm8
    Snippet: The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19. The antiviral effects could be detected in both human and non-human cells, without
    Document: The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is a candidate as an oral antiviral drug for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1
    Co phrase search for related documents, hyperlinks ordered by date